Preparation of F (ab’) 2 trastuzumab fragment for Radioimmunoconjugate synthesis of 177Lu-DOTA-F (ab’)2- trastuzumab (original) (raw)

The research focuses on the preparation of a F(ab')2 fragment of trastuzumab, aiming to enhance the efficacy of cancer radioimmunotherapy using 177Lu-DOTA. The study addresses the limitations of using intact monoclonal antibodies (mAbs) in treatment due to their larger size, which hampers effective tumor targeting and increases radiation exposure to healthy tissues. The proposed solution involves the synthesis of a smaller Fab fragment conjugated with a bifunctional chelating agent, facilitating faster and more targeted delivery of radioimmunoconjugates. In vitro and in vivo tests will verify the fragment's radiochemical purity, stability, and immunoreactivity, while computational modeling will elucidate its interaction with HER2.